- Home
- OTLK vs LXEH Comparison
OTLK vs LXEH Comparison
Compare OTLK & LXEH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- LXEH
- Stock Information
- Founded
- OTLK 2010
- LXEH 2001
- Country
- OTLK United States
- LXEH China
- Employees
- OTLK N/A
- LXEH N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- LXEH Other Consumer Services
- Sector
- OTLK Health Care
- LXEH Real Estate
- Exchange
- OTLK Nasdaq
- LXEH Nasdaq
- Market Cap
- OTLK 48.3M
- LXEH 55.2M
- IPO Year
- OTLK 2016
- LXEH 2020
- Fundamental
- Price
- OTLK $2.34
- LXEH $1.40
- Analyst Decision
- OTLK Strong Buy
- LXEH
- Analyst Count
- OTLK 5
- LXEH 0
- Target Price
- OTLK $9.60
- LXEH N/A
- AVG Volume (30 Days)
- OTLK 1.1M
- LXEH 735.0K
- Earning Date
- OTLK 08-14-2025
- LXEH 09-15-2025
- Dividend Yield
- OTLK N/A
- LXEH N/A
- EPS Growth
- OTLK N/A
- LXEH N/A
- EPS
- OTLK N/A
- LXEH N/A
- Revenue
- OTLK $1,505,322.00
- LXEH $4,493,795.00
- Revenue This Year
- OTLK N/A
- LXEH N/A
- Revenue Next Year
- OTLK $407.74
- LXEH N/A
- P/E Ratio
- OTLK N/A
- LXEH N/A
- Revenue Growth
- OTLK N/A
- LXEH N/A
- 52 Week Low
- OTLK $0.87
- LXEH $1.12
- 52 Week High
- OTLK $8.32
- LXEH $50.08
- Technical
- Relative Strength Index (RSI)
- OTLK 63.83
- LXEH 44.48
- Support Level
- OTLK $1.95
- LXEH $1.12
- Resistance Level
- OTLK $2.14
- LXEH $1.83
- Average True Range (ATR)
- OTLK 0.17
- LXEH 0.43
- MACD
- OTLK 0.03
- LXEH -0.06
- Stochastic Oscillator
- OTLK 77.62
- LXEH 15.73
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.